IP Library Granted Patent US 8,470,308
Granted Patent B2
US 8,470,308 · App. 12/655,633 · Granted Jun 25, 2013

Enhanced medical implant comprising disrupted tooth pulp and tooth particles

Inventor: Ray C. Wasielewski (New Albany, OH)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,470,308
App. No.
12/655,633
Granted
Jun 25, 2013
Kind
B2
Abstract

A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Tooth stem cells may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the tooth stem cells can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair.

Claims (13)

1. A medical treatment composition comprising:

physically disrupted, non-collagenase-digested tooth pulp including a plurality of stem cells; and

a plurality of ground mammalian tooth particles.

2. The medical treatment composition of claim 1 , wherein the plurality of ground mammalian tooth particles includes dentin, enamel, or mixtures thereof.

3. The medical treatment composition of claim 1 , wherein the plurality of ground mammalian tooth particles includes particles of tooth derived hydroxyapatite.

4. The medical treatment composition of claim 1 , wherein the plurality of ground mammalian tooth particles includes one or more endogenous or exogenous growth factors.

5. The medical treatment composition of claim 4 , wherein the one or more endogenous or exogenous growth factors are chosen from transforming growth factor beta, insulin like growth factor I, insulin like growth factor II, platelet-derived growth factor, fibroblast growth factor, and bone morphogenetic proteins.

6. The medical treatment composition of claim 1 , wherein the physically disrupted, non-collagenase-digested tooth pulp is selected from the group consisting of a diced tooth pulp, a minced tooth pulp, and combinations thereof.

7. The medical treatment composition of claim 1 , wherein the physically disrupted, non-collagenase-digested tooth pulp is a sterilized, physically disrupted, non-collagenase digested tooth pulp, and wherein the sterilized, physically disrupted, non-collagenase digested tooth pulp includes a plurality of stem cells that are living.

8. The medical treatment composition of claim 1 , wherein the plurality of stem cells includes pluripotent stem cells.

9. The medical treatment composition of claim 1 , wherein the plurality of ground mammalian tooth particles have a mean particle size in the range of 5 μm to 100 μm.

10. The medical treatment composition of claim 1 , wherein the plurality of ground mammalian tooth particles have a mean particle size in the range of 100 μm to 500 μm.

11. The medical treatment composition of claim 1 , wherein the plurality of ground mammalian tooth particles have a mean particle size in the range of 500 μm to 1,000 μm.

Continuity (2)
Continuation In Part 12348280 · Jan 3, 2009
Related Publication 20100172863A1 · Jul 8, 2010